Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii …
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections
Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE …
M Bassetti, R Echols, Y Matsunaga… - The Lancet infectious …, 2021 - thelancet.com
Background New antibiotics are needed for the treatment of patients with life-threatening
carbapenem-resistant Gram-negative infections. We assessed the efficacy and safety of …
carbapenem-resistant Gram-negative infections. We assessed the efficacy and safety of …
The value of antimicrobial peptides in the age of resistance
M Magana, M Pushpanathan, AL Santos… - The lancet infectious …, 2020 - thelancet.com
Accelerating growth and global expansion of antimicrobial resistance has deepened the
need for discovery of novel antimicrobial agents. Antimicrobial peptides have clear …
need for discovery of novel antimicrobial agents. Antimicrobial peptides have clear …
Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii
M Falcone, G Tiseo, A Leonildi… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter
baumannii (CRAB) infections, but clinical data are limited. This is an observational …
baumannii (CRAB) infections, but clinical data are limited. This is an observational …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki… - … : The Journal of …, 2019 - Wiley Online Library
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase–producing Enterobacterales
Background In vitro data support the use of combination of aztreonam (ATM) with
ceftazidime-avibactam (CAZ-AVI), but clinical studies are lacking. The aim of our study was …
ceftazidime-avibactam (CAZ-AVI), but clinical studies are lacking. The aim of our study was …
[HTML][HTML] Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
CC Sheu, YT Chang, SY Lin, YH Chen… - Frontiers in …, 2019 - frontiersin.org
Carbapenems are considered as last-resort antibiotics for the treatment of infections caused
by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in …
by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in …